In this section

Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

Schett, G., Chen, W., Gao, S., Chakravarty, S. D., Shawi, M., Lavie, F., Zimmermann, M., Sharaf, M., Coates, L. C. and Siebert, S. (2023) Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. Arthritis Research and Therapy, 25(1), 170. (doi: 10.1186/s13075-023-03158-9) (PMID:37715280) (PMCID:PMC10503169)

[img] Text
310911.pdf - Published Version
Available under License Creative Commons Attribution.
1MB

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Siebert, Professor Stefan
Authors: Schett, G., Chen, W., Gao, S., Chakravarty, S. D., Shawi, M., Lavie, F., Zimmermann, M., Sharaf, M., Coates, L. C., and Siebert, S.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Arthritis Research and Therapy
Publisher:BioMed Central
ISSN:1478-6354
ISSN (Online):1478-6362
Copyright Holders:Copyright © 2023 The Authors
First Published:First published in Arthritis Research and Therapy 25:170
Publisher Policy:Reproduced under a Creative Commons licence

University Staff: Request a correction | Enlighten Editors: Update this record

Deposit and Record Details